<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">

TriviumVet launch the HALT HCM Study recruiting 300 cats with diagnosed subclinical Hypertrophic Cardiomyopathy (HCM)

We at TriviumVet are thrilled to announce that the long-awaited HALT HCM Study is now live and recruiting cats in cardiac care centers across the United States! The study was officially launched at this year’s American College of Veterinary Internal Medicine (ACVIM) in Minneapolis.

The HALT Study is a pivotal, placebo-controlled trial designed to determine the effectiveness of TRIV202 in managing left ventricular hypertrophy associated with feline Hypertrophic Cardiomyopathy (HCM) over a 12-month period.

The study is now open for recruitment, enrolling cats diagnosed with subclinical HCM offering care from a board-certified veterinary cardiologist FREE OF CHARGE.

For more information on The HALT Study, including current study sites, enrolment criteria, or to register your cat or a patient, visit www.hcmincats.com.